Trenton, October 11, 2024 — The HealthCare Institute of New Jersey has expressed concerns regarding the Federal Trade Commission's recent finalization of Hart-Scott-Rodino (HSR) premerger notification rules. According to the statement released by the institute, these new regulations could significantly impact New Jersey's life sciences sector.
"The final HSR rules as issued by the Federal Trade Commission will impose a significant burden on the future of New Jersey’s life sciences community and our ability to do what we do best – saving lives around the world by finding new treatments and cures in New Jersey," stated the HealthCare Institute of New Jersey.
The institute emphasized that mergers and acquisitions have historically been crucial in advancing discoveries from research to patient care within the state. They warned that "these rules could lead to additional costs far exceeding what many early-stage biopharmaceutical or medical technology companies are able to shoulder."
The statement concluded with an appeal to federal policymakers: "We implore federal policymakers to recognize the potential damage these policies could inflict on New Jersey’s life sciences ecosystem and our state’s workforce and economy, and to restore bipartisan balance to merger and acquisition enforcement in the life sciences."
